A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100°C measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50°C at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
一种组合物包括一种固体分散体,其中包含一种低溶解度药物和至少一种聚合物。分散体中的药物至少有一大部分是无定形的。聚合物在相对湿度为百分之五十时的
玻璃化温度至少为 100°C。本发明的另一方面包括相同的组合物,但分散体在相对湿度为百分之五十时的
玻璃化温度至少为 50°C。在本发明的另一方面,一种组合物包括一种固体分散体,其中包含一种低溶解度药物和一种稳定聚合物。分散体中的药物至少有一大部分是无定形的。该组合物还包括一种浓度增强聚合物,可提高药物在使用环境中的浓度。在相对湿度为 50%时,稳定聚合物的
玻璃化转变温度大于浓度增强聚合物的
玻璃化转变温度。